Clinical Trials Browser

Interventional × rucaparib × Genitourinary × Clear all

Prostatic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 1 FDA

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

18 enrolled

Genitourinary

ATM Gene Mutation

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

13 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03413995 2024-10-16

TRIUMPH

Phase 2 Completed

12 enrolled 11 charts

Genitourinary

Prostate Cancer Metastatic

NCT04676334 2024-05-07

CATCH-R

Phase 3 Completed

34 enrolled 9 charts

GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT03533946 2024-03-13

ROAR

Phase 2 Terminated

7 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Phase 1/2 Terminated

25 enrolled 11 charts

BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Phase 1 Completed

51 enrolled 20 charts

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03572478 2021-03-09

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

GenitourinaryGynecologic

Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

CheckMate 9KD

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

TRITON3

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

TRIUMPH

CATCH-R

ROAR

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

LODESTAR

RAMP

ATLAS

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer